ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1724

The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment

Majed Khraishi1, Alice B. Gottlieb2, Bengt Hoepken3, Luke Peterson4 and Philip J. Mease5, 1Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Tufts University School of Medicine, Boston, MA, 3UCB Pharma, Monheim, Germany, 4UCB Pharma, Raleigh, NC, 5Swedish Medical Center and University of Washington, Seattle, WA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: certolizumab pegol, extraarticular manifestations, psoriasis and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The majority of patients (pts) with psoriatic arthritis (PsA) experience psoriatic skin manifestations, which add to the already high burden of disease. The RAPID-PsA trial (NCT01087788) of certolizumab pegol (CZP) in PsA has shown CZP to be efficacious in improving skin manifestations over 96 weeks (wks) of treatment.1 Here, we report long-term efficacy data for skin manifestations over 4 years of the RAPID-PsA trial.

Methods: The phase 3 RAPID-PsA trial was double-blind and placebo-controlled to Wk 24, dose-blind to Wk 48 and open-label (OL) to Wk 216. Pts had active PsA and had failed ≥1 DMARD; up to 40% of pts could have received 1 prior anti-TNF. Pts originally randomized to CZP (200 mg Q2W or 400 mg Q4W, following 400 mg loading dose at Wks 0, 2, 4) continued on their assigned dose in the OL period. Here we report outcomes assessing the skin manifestations of PsA in CZP-randomized pts with skin involvement at baseline (≥3% body surface area affected by psoriasis [BSA]). Data are shown as observed case (OC) and with imputation: NRI for categorical measures and LOCF for continuous measures.

Results: Of the 409 pts randomized, 273 received CZP from Wk 0, 166 of whom had baseline skin involvement (≥3% BSA). At baseline, these patients had an average of 24.2% BSA and a mean PASI score of 12.0. Severe skin involvement (≥3% BSA and PASI ≥10) was seen in 71 pts at baseline, with an average of 38.7% BSA affected and a mean PASI score of 22.3 amongst these pts. In pts completing the study, early improvements in PASI responses observed to Wk 241 were sustained to Wk 216 following treatment with either dose regimen (Table). Even when conservative imputation methods (NRI) were used, PASI responses were largely maintained, with an increased proportion of pts achieving the most stringent outcome, PASI100 (NRI; Wk 24: 22.3%, Wk 216: 28.3%). Similar sustained improvements were observed in both mean BSA and mean PASI score (Table). At Wk 48, 77.5% of pts with severe skin involvement at baseline (PASI ≥10) achieved a PASI75 response, compared with 54.7% of pts with less severe baseline skin involvement (PASI <10) (NRI). The heightened response in the most severely affected pts remained evident at Wk 216 (PASI75 [NRI]: PASI ≥10: 59.2%, PASI <10: 46.3%).

Conclusion: Improvements in the skin manifestations of PsA, as seen at Wk 24,1 were maintained over 4 years of CZP treatment with both dose regimens, with additional improvements observed at Wk 216 in the proportion of pts achieving the most stringent measure, the PASI100 response. The increased PASI75 response rate previously observed in pts with severe skin involvement relative to those with less severe skin manifestations was also maintained to Wk 216. References: 1. Mease P. Ann Rheum Dis 2014;73:48–55


Disclosure: M. Khraishi, Abbott Laboratories, Amgen, Pfizer, 2; A. B. Gottlieb, Abbott, Actelion, Akros, Astellas, Beiersdorf, CSL Behring, Bristol-Myers Squibb, Can-Fite, Catabasis, Celgene, Centocor, Coronado, CSL Dermipsor, GlaxoSmithKline, Incyte, Karyopharm, Eli Lilly, Mej, Novartis, Novo Nordisk, Pfizer, TEVA, UCB Pharma, Vert, 5,Abbott, Amgen, Baxalta, Celgene, Centocor, Coronado, Dermira, Levia, Eli Lilly, Merck, Novartis, Pfizer, Xenoport, 2; B. Hoepken, Employee of UCB, 3; L. Peterson, Employee of UCB, 3; P. J. Mease, Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sun, UCB Pharma, 2,Abbive, Amgen, Bristol-Myers Squibb, Celgene, Crescendo, Corrona, Dermira, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Sun, UCB Pharma, Zynerba, 5,Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Crescendo, Genentech, Janssen, Novartis, Pfizer, UCB Pharma, 8.

To cite this abstract in AMA style:

Khraishi M, Gottlieb AB, Hoepken B, Peterson L, Mease PJ. The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-effect-of-certolizumab-pegol-on-skin-manifestations-of-psoriatic-arthritis-over-4-years-of-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-certolizumab-pegol-on-skin-manifestations-of-psoriatic-arthritis-over-4-years-of-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology